FSD Pharma aims to initiate a Phase 2 coronavirus treatment trial by end 2020 as it files IND

fsd
Written By Padilla Development

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE.CN) (FRA:0K9A) CEO Raza Bokhari tells Proactive the group has submitted an Investigational New Drug (IND) application to the FDA for the use of its lead candidate FSD-201, or anti-inflammatory ultra-micronized-palmitoylethanolamide (PEA), to treat coronavirus patients.

Bokhari says hopefully before the end of 2020, the group will initiate a Phase 2 trial to treat hospitalized coronavirus patients.

Click here to watch the video.

Padilla Development
Previous

FSD Pharma Inc. Rings the Opening Bell
Next

Full interview: FSD Pharma rings the bell to open trading day on the Canadian Securities Exchange